Hepatocellular Carcinoma Clinical Trials in Tianjin
5 recruitingTianjin, China
Showing 1–5 of 5 trials
Recruiting
Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma (HCC)
Shanghai Henlius Biotech246 enrolled51 locationsNCT07176650
Recruiting
Phase 2
Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma
Hepatocellular Carcinoma
AstraZeneca114 enrolled24 locationsNCT07081633
Recruiting
Phase 3
Study of Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With Unresectable Hepatocellular Carinoma
Hepatocellular Carcinoma
AstraZeneca210 enrolled32 locationsNCT05557838
Recruiting
Not Applicable
TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors
Liver MetastasesCholangiocarcinoma Non-resectableLiver Malignant Tumors+1 more
Tianjin Medical University Cancer Institute and Hospital40 enrolled1 locationNCT06487663
Recruiting
Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular Carcinoma
Hepatocellular Carcinoma
Singlera Genomics Inc.2,000 enrolled3 locationsNCT05626985